Development of Therapeutic Proteins for a New Subcutaneous Route of Administration after the Establishment of Intravenous Dosages: A Systematic Review
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration after the Establishment of Intravenous Dosages: A Systematic Review
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-12-15
DOI
10.1002/cpt.2823
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective
- (2022) Tao Liu et al. LUPUS
- Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
- (2021) Stefan Schreiber et al. GASTROENTEROLOGY
- Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review
- (2021) Paul M Overton et al. Patient Preference and Adherence
- Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
- (2021) Séverine Vermeire et al. Journal of Crohns & Colitis
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
- (2021) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study
- (2020) Ajai Chari et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial
- (2020) Rene Westhovens et al. RHEUMATOLOGY
- A novel pharmacokinetic bridging strategy to support a change in the route of administration for biologics
- (2019) Ping Ji et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Rituximab dosing in hematological malignancies: an old question, revisited
- (2019) Peter N. Morcos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
- (2018) Beate Bittner et al. BIODRUGS
- Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
- (2017) Pieternella Lugtenburg et al. HAEMATOLOGICA
- Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins
- (2017) Lora Hamuro et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Fixed Dosing of Monoclonal Antibodies in Oncology
- (2017) Jeroen J.M.A. Hendrikx et al. ONCOLOGIST
- Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
- (2017) Pieternella Lugtenburg et al. HAEMATOLOGICA
- Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
- (2017) William Stohl et al. Arthritis & Rheumatology
- Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
- (2016) M. Rummel et al. ANNALS OF ONCOLOGY
- Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
- (2015) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
- (2015) Sarit Assouline et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
- (2014) Antonio Salar et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
- (2014) Andrew Davies et al. LANCET ONCOLOGY
- Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
- (2014) Alan Kivitz et al. ARTHRITIS CARE & RESEARCH
- Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial
- (2012) Michael E Weinblatt et al. ANNALS OF THE RHEUMATIC DISEASES
- Rational development and utilization of antibody-based therapeutic proteins in pediatrics
- (2012) Zhenhua Xu et al. PHARMACOLOGY & THERAPEUTICS
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
- (2011) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study
- (2010) Joel Kremer et al. ARTHRITIS AND RHEUMATISM
- Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis
- (2010) Denis Mulleman et al. THERAPEUTIC DRUG MONITORING
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
- (2008) E C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation